title: Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?
abstract: The constitutive activation of phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway has been demonstrated to be critical in clinical cancer patients as well as in laboratory cancer models including hematological malignancies. Great efforts have been made to develop inhibitors targeting this pathway in hematological malignancies but so far the efficacies of these inhibitors were not as good as expected. By analyzing existing literatures and datasets available, we found that mutations of genes in the pathway only constitute a very small subset of hematological malignancies. Deep understanding of the function of gene, the pathway and/or its regulators, and the cellular response to inhibitors, may help us design better drugs targeting the hematological malignancies.
authors: State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China ;
authors: Yanan
authors: Y
authors: Gao
authors: State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China;; College of Arts and Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
authors: Chase Y
authors: CY
authors: Yuan
authors: State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China ;
authors: Weiping
authors: W
authors: Yuan
keywords: Phosphatidylinositol 3-kinase (PI3K); genetic analysis; hematological malignancies; mammalian target of rapamycin (mTOR); protein kinase B (Akt)